IMUX

Immunic, Inc. (IMUX) | Rumor.io

Immunic

IMUX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,040

Bullish sentiment (50-day avg)82%

Price to earnings ratio-1.54

Market capitalization129.8M

Earnings per share-3.55

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-97.2M

Social

What share of all stock conversation is about IMUX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

May 28

Immunic, Inc. (IMUX) presented additional Phase 2 CALLIPER trial data for vidofludimus calcium at the CMSC Annual Meeting 2026, showing a favorable safety and tolerability profile and patient-reported outcomes.
The data highlighted no negative impact on mood and a comparable safety profile to placebo, with Phase 3 ENSURE data expected by end of 2026.
The company is building a strong team ahead of Phase 3, with several key hires from major MS treatment companies, including Genentech and Sanofi.

Generated by AI

Sentiment

Of the messages about IMUX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	77.78% -22.22	82.76% +2.76	86.44% +7.45
Bearish	—	22.22% +22.22	17.24% -2.76	13.56% -7.45

Bullish· Feb 27

$IMUX is expected to reach $2 organically, with a long-term target of $8.00 to $10.00.
A $400 million investor has increased their position in the company, potentially driving the stock price higher.
The stock has already seen a significant price increase following its earnings release, with a 9.7% gain post-announcement.

Bearish· Feb 13

$IMUX is expected to face resistance at 1.28, 1.40, 1.55, and 1.90, with support at 1.06.
The stock is being manipulated to keep the downtrend momentum going, and a reverse stock split (R/S) is a strong possibility.
The company's disappointing new filing and excessive dilution make it a candidate for shorting, and the stock may be due for a significant drop to $1.90.

Generated by AI

Topics

Of the messages about IMUX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	75%	26.21%
Analysts	—	—	0%	35.06%
Controversies	—	—	25%	0.19%
Earnings	—	—	0%	0%
Macro	—	—	0%	33.05%
Technical Analysis	—	—	0%	5.49%

Announcements· Feb 13

Immunic, Inc. (IMUX) has secured a private placement of up to $400 million to accelerate its transformation into a commercial-stage company.
The company will begin a search for a new CEO with deep commercial expertise in the multiple sclerosis space to lead the company through its next stage of growth and into commercialization.
The new financing will be used to propel the company's multiple sclerosis programs and commercial transition, with top-line data expected by the end of 2026 and a New Drug Application (NDA) submission in the United States in mid-2027.

Technical Analysis· Apr 5

$IMUX has a possible double top formation at $1.93, with a target of $2+ if it breaks the double top.
The daily chart shows a green MacD, indicating a potential reversal, with a major resistance level at $2.07 on the 4h chart.
The stock has a strong momentum and volume, with a break of the $2.08 area showing more room on the chart, targeting $2.43-$2.92.

Generated by AI

Community

Of the messages about IMUX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	61.29%	43.09%	43.92%
Newcomers	0%	38.71%	56.91%	56.08%

Regulars· Feb 13

Immunic, Inc. has secured a $400 million private placement to accelerate its transformation into a commercial-stage company, with plans to use the funding to support NDA submission in mid-2027 and top-line Phase 3 ENSURE data by end-2026.
The company will also seek a new CEO with commercial expertise in multiple sclerosis to lead the firm through its next growth stage and into commercialization.
The private placement includes the issuance of warrants to purchase up to 229.1 million shares at $0.873 per share, potentially raising an additional $200 million, which will expire 30 days post-Phase 3 ENSURE top-line data announcement or February 17, 2031.

Newcomers· Feb 13

The company, Immunic, Inc., has secured a $400 million private placement to accelerate its transformation into a commercial-stage company, which has led to a significant increase in its stock price.
The influx of fresh capital from institutional investors, including BVF and OrbiMed, has sparked optimism among market participants, who see this as a vote of confidence in the company's future prospects.
The company's plans to submit a New Drug Application (NDA) in the United States in mid-2027, with a targeted potential regulatory approval date in 2028, has been highlighted as a key catalyst for the stock's upward momentum.

Generated by AI

News

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

9d agoBarchart.com

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

12d agoSeeking Alpha

Immunic announces resignation of director Duane Nash and board size reduction

18d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)

Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

19d agoSeeking Alpha

Stifel reiterates Immunic stock rating on MS drug potential

19d agoInvesting.com

Also Discussed

Investors talking about IMUX also mention

#	Name	Attention
1	Precipio Inc.PRPO	0%0
2	Invesco High Income Trust IIVLT	0%0
3	InflaRx N.V.IFRX	0%new
4	Bio-Path Holdings Inc.BPTH	0%0
5	Protara Therapeutics, Inc.TARA	0%0
6	Legacy Education Inc.LGCY	0%new
7	Alpha Metallurgical Resources, Inc.AMR	0%0
8	FPAY - FlexShopper, Inc.	——
9	ATA Creativity GlobalAACG	0%new
10	OUTFRONT Media Inc.OUT	0%0

Immunic, Inc.

Healthcare
Biotechnology

Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.

Website

Location

1200 Avenue of the Americas

New York, NY, 10036

United States

Social

What share of all stock conversation is about IMUX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

May 28

Immunic, Inc. (IMUX) presented additional Phase 2 CALLIPER trial data for vidofludimus calcium at the CMSC Annual Meeting 2026, showing a favorable safety and tolerability profile and patient-reported outcomes.
The data highlighted no negative impact on mood and a comparable safety profile to placebo, with Phase 3 ENSURE data expected by end of 2026.
The company is building a strong team ahead of Phase 3, with several key hires from major MS treatment companies, including Genentech and Sanofi.

Generated by AI

Sentiment

Of the messages about IMUX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	77.78% -22.22	82.76% +2.76	86.44% +7.45
Bearish	—	22.22% +22.22	17.24% -2.76	13.56% -7.45

Bullish· Feb 27

$IMUX is expected to reach $2 organically, with a long-term target of $8.00 to $10.00.
A $400 million investor has increased their position in the company, potentially driving the stock price higher.
The stock has already seen a significant price increase following its earnings release, with a 9.7% gain post-announcement.

Bearish· Feb 13

$IMUX is expected to face resistance at 1.28, 1.40, 1.55, and 1.90, with support at 1.06.
The stock is being manipulated to keep the downtrend momentum going, and a reverse stock split (R/S) is a strong possibility.
The company's disappointing new filing and excessive dilution make it a candidate for shorting, and the stock may be due for a significant drop to $1.90.

Generated by AI

Topics

Of the messages about IMUX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	75%	26.21%
Analysts	—	—	0%	35.06%
Controversies	—	—	25%	0.19%
Earnings	—	—	0%	0%
Macro	—	—	0%	33.05%
Technical Analysis	—	—	0%	5.49%

Announcements· Feb 13

Immunic, Inc. (IMUX) has secured a private placement of up to $400 million to accelerate its transformation into a commercial-stage company.
The company will begin a search for a new CEO with deep commercial expertise in the multiple sclerosis space to lead the company through its next stage of growth and into commercialization.
The new financing will be used to propel the company's multiple sclerosis programs and commercial transition, with top-line data expected by the end of 2026 and a New Drug Application (NDA) submission in the United States in mid-2027.

Technical Analysis· Apr 5

$IMUX has a possible double top formation at $1.93, with a target of $2+ if it breaks the double top.
The daily chart shows a green MacD, indicating a potential reversal, with a major resistance level at $2.07 on the 4h chart.
The stock has a strong momentum and volume, with a break of the $2.08 area showing more room on the chart, targeting $2.43-$2.92.

Generated by AI

Community

Of the messages about IMUX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	61.29%	43.09%	43.92%
Newcomers	0%	38.71%	56.91%	56.08%

Regulars· Feb 13

Immunic, Inc. has secured a $400 million private placement to accelerate its transformation into a commercial-stage company, with plans to use the funding to support NDA submission in mid-2027 and top-line Phase 3 ENSURE data by end-2026.
The company will also seek a new CEO with commercial expertise in multiple sclerosis to lead the firm through its next growth stage and into commercialization.
The private placement includes the issuance of warrants to purchase up to 229.1 million shares at $0.873 per share, potentially raising an additional $200 million, which will expire 30 days post-Phase 3 ENSURE top-line data announcement or February 17, 2031.

Newcomers· Feb 13

The company, Immunic, Inc., has secured a $400 million private placement to accelerate its transformation into a commercial-stage company, which has led to a significant increase in its stock price.
The influx of fresh capital from institutional investors, including BVF and OrbiMed, has sparked optimism among market participants, who see this as a vote of confidence in the company's future prospects.
The company's plans to submit a New Drug Application (NDA) in the United States in mid-2027, with a targeted potential regulatory approval date in 2028, has been highlighted as a key catalyst for the stock's upward momentum.

Generated by AI

Immunic

Social

May 28

Bullish· Feb 27

Bearish· Feb 13

Announcements· Feb 13

Technical Analysis· Apr 5

Regulars· Feb 13

Newcomers· Feb 13

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

Immunic announces resignation of director Duane Nash and board size reduction

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

Stifel reiterates Immunic stock rating on MS drug potential

Also Discussed

Immunic, Inc.

Company Information

Location

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

Immunic announces resignation of director Duane Nash and board size reduction

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10

Stifel reiterates Immunic stock rating on MS drug potential

Also Discussed

Social

May 28

Bullish· Feb 27

Bearish· Feb 13

Announcements· Feb 13

Technical Analysis· Apr 5

Regulars· Feb 13

Newcomers· Feb 13